2013 ANNUAL REPORT
Ian Davis
Chairman’s Report I am pleased to provide a report outlining ANZUP’s continued growth and success over the last twelve months. In early 2012 the Board reviewed our progress towards achieving the objectives of the ANZUP Strategic Plan 2010-2012. It was clear that ANZUP had achieved virtually all of its objectives in that period and that the only objectives not achieved were in large part due to circumstances beyond our control, such as ability to secure project-specific funding for certain trials. Objectives that were not able to be achieved have been rolled into the new ANZUP Strategic Plan 2013-2015, endorsed by the Board in May 2012 and available for your perusal on our web site: http://www.anzup.org.au/content.aspx?page=strategicplan Briefly, the ANZUP Strategic Plan 2013-2015 calls for actions in the following areas, all of which align with the objectives of the Company and its mission:
We are already well advanced in achieving most of these objectives. An aspirational objective is to perform research addressing specific health and medical issues of culturally and linguistically diverse groups, Aboriginal and Torres Strait Islanders and Maori people. To date opportunities for this have not been realised but we will continue to work towards this. The following points illustrate some of the highlights of our most recent year: • Successful completion of accrual to the EVERSUN and SORCE trials. EVERSUN is an ANZUP-initiated trial that has drawn international interest. ANZUP was the largest contributor to SORCE outside the UK, contributing about 10% of the total accrual. • Publication of several trials including key papers for testicular cancer studies.
• Improvement and strengthening of links with key stakeholders and other cooperative groups;
• Development of new trial proposals for prostate, renal, urothelial and testicular cancers.
•
• Successful procurement of funding for the phase III BEP testicular cancer trial and the BCG-MMC non-muscle-invasive bladder cancer trial.
Development of trials in each of the disease areas we cover;
• Early and regular inclusion of the Consumer Advisory Panel, Correlative and Translational Research Subcommittee, and Quality of Life and Supportive Care Subcommittee; • Expansion and engagement of the Consumer Advisory Panel at all levels of the organisation; • Provision of forums for intellectual exchange and protocol development, including our Annual Scientific Meeting; •
Building opportunities for younger researchers and trainees;
• Improving resources for ANZUP including pro-active fundraising initiatives; •
Continuing to increase our membership;
•
Provision of regular communication to members.
10
• Forging of new links with industry and other cooperative trial groups leading to new trial opportunities, hopefully to begin within the next year. • Development of our Corporate Supporter program. We thank our current corporate supporters: Amgen, Bayer, Ipsen, Pfizer and Sanofi. • Review of our governance model, including review of the committee Terms of Reference and identification of Deputy Chairs to secure succession planning. • Expanded the CAP membership to include representation across the four major GU cancers to ensure more effective consumer involvement
